- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Australia Plans to Expedite Drug Approval Process
September 20, 2016
BioCentury
reports that Australia's Therapeutic Goods Administration (TGA) is planning to implement new approval pathways in an effort to improve and speed access to therapeutics. Among the new pathways reported is an expedited approval pathway that allows for accelerated assessment of new medicines - potentially allowing them to come to market three months sooner than the current framework -and a provisional approval pathway, which could speed up approval by as much as two years. For more on this story,
click here
.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
